glp-1 obesity drug updates The FDA approved a new pill from Eli Lilly on Wednesday. The drug, called Foundayo, is the second GLP-1 weight-loss pill. CBS News' Dr. LaPook has more on the new medication Upcoming wave of hormone-based therapies

(Another DPP-4 inhibitor, vildagliptin, is widely prescribed in Europe but is not available in the U.S.) These agents are also available in combination with other diabetes medications (i.e., metformin, empagliflozin, pioglitazone, dapagliflozin, ertugliflozin)

And in this comparison, the clinical data is devastating for phentermine

All 122,124,125,126,127,128 but one 123 study showed a benefit on metabolic parameters

OZEMs fourth-largest holding, with a 4.41% weighting, Viking Therapeutics NASDAQ: VKTX, currently has its dual GLP-1/GIP agonist, VK2735, in advanced clinical trials for obesity and metabolic disorders

Additionally, the appetite-suppressing effects of GLP-1 medications can partially attenuate over time as receptors adjust to sustained stimulation

It is available under the brand name Rybelsus